kills tumor cells in the dreaded glioblastoma -- at least in the cell-culture ... Sep. 9, 2024 — A study has discovered that recurrent tumors of the aggressive brain cancer glioblastoma ...

The global Cell Therapy Technologies market, valued at US$3.89 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, ...

The Biochemistry Cell Culture Facility provides investigators within the Department a user-friendly, shared resource environment where researchers can advance discovery in diverse areas such as cancer ...

Jan. 10, 2025 — A study shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer. Investigators examined how molecular dynamics at the ...

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

The newly approved methastatic Renal Cell Cancer (mRCC) Phase 1/2a trial began in Q4 2024, and Genenta expects to treat six patients by the end of the first half of 2025, while continuing progress ...

Professor Michel Sadelain, of Canadian origins,was announced the 2025 laureate for King Faisal Prize in Medicine forhis ...

Cancer-associated fibroblasts (CAF) generate an extracellular matrix (ECM) which provides a repository for factors that promote pancreatic cancer progression. Here, we establish that CAF contribution ...

Henrietta Lacks died of cancer in 1951, but her cells mysteriously kept on living. Since then her "immortal" cell line has ...

IL-2 Heat Stable Agonist: Engineered with enhanced thermal stability and altered receptor affinity for improved biological activity, ideal for cellular therapy applications such as CAR T-cell or Tumor ...